
Principles of Ocular Oncology

Hatem Krema

Principles of Ocular Oncology

 Springer

Hatem Crema
Ocular Oncology Service,
Princess Margaret Cancer Centre/
University Health Network
University of Toronto
Toronto, ON, Canada

ISBN 978-3-031-82952-9 ISBN 978-3-031-82953-6 (eBook)
<https://doi.org/10.1007/978-3-031-82953-6>

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2025

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

If disposing of this product, please recycle the paper.

To the eye tumor patients and their families, I have learned from your endurance.

To my teachers and mentors, I will always remain indebted to each one of you.

To the future ocular oncologists, keep learning and innovating.

To my family, I am deeply grateful for your continuous support.

Foreword

Importance of the Field of Ocular Oncology

The field of Ophthalmology is broad and is primarily dedicated to the study of the structure, function, and diseases of the eye, with the ultimate goal of protecting visual acuity. An important subfield of Ophthalmology is Ocular Oncology, which includes the study of cancers of the eye region involving the eyelids, conjunctiva, orbit, and intraocular structures. The goals of management in Ocular Oncology are more profound and more overwhelming as the focus is on saving the patient's life, then protecting the patient's eye, and lastly, safeguarding visual acuity. Indeed, Ocular Oncology is a vital subspecialty of Ophthalmology and perhaps more challenging than other subspecialties as it involves a patient's life.

Years ago, the management of ocular cancers was somewhat haphazard with little interest in the field as ocular cancers were deemed rare. However, in the 1970s, the field of Ocular Oncology was born. Five centers in North America were developing in Boston, New York, San Francisco, Philadelphia, and Toronto. As interest in the field grew, it was realized that ocular cancers might be more prevalent than suspected and required a high level of expertise for appropriate diagnosis and proper management. Diagnostic imaging for tumor detection developed and was studied including methods of fluorescein angiography, ultrasonography, computed tomography, and magnetic resonance imaging. Later, optical coherence tomography and fine-needle aspiration biopsy for cytologic and cytogenetic testing were perfected. The field of Ocular Oncology was maturing and demonstrating great forward strides.

Soon thereafter, more centers flourished worldwide, including the powerful center in Toronto, under the direction of Dr. Hatem Krema. Centers were created in Turkey, Italy, Spain, Sweden, Ireland, Finland, Israel, Argentina, Chile, India, Japan, China, Nigeria, South Africa, and others. Despite this progress, there remain numerous areas worldwide that are devoid of Ocular Oncology, and patients struggle to receive appropriate care.

In this book, Dr. Krema shares his knowledge on the basics of oncology and available treatment methods, and then elaborates on the specific tumors of the eyelids, ocular surface, orbit, and intraocular structures, including the uvea, retina, and optic disc. In addition, he explores the eye in systemic cancers, including solid cancers and hematopoietic cancers, such as leukemia, lymphoma, plasma cell neoplasia, and histiocytosis. He further educates us on systemic cancers that can lead to ophthalmic paraneoplastic syndromes, and he describes some of the ocular toxicities that result from systemic chemotherapy, targeted therapy, and immunotherapy.

The precious vitality of this book begins with an understanding of "What is oncology?" In Chap. 1, Dr. Krema touches upon regulation of the cell cycle and cell signaling, gene mutations, hereditary cancer syndromes, carcinogens, and epigenetics that can all contribute to cancer. In Chap. 2, principles of surgery, radiotherapy, laser therapy, cryotherapy, chemotherapy, and targeted therapy are discussed. The targeted therapy section is robust with discussion on the Hedgehog pathway, mTOR pathway, and inhibitors of BRAF, MEK, HIF-2 α , protease, and protein kinase C, all of which are crucial in our understanding and management of cancers. That section is a "must-read" segment to improve understanding of how medications work.

As the clinical portion of the book unfolds, Chap. 3 focuses on eyelid tumors with a discussion on clinical features and management of over 50 various eyelid tumors, with comprehensive organization into epidermal, sebaceous, melanocytic, neural, vascular, sweat gland, hair follicle, and metastatic origins. Similarly, well-organized Chap. 4 on ocular surface tumors, Chap. 5 on orbital tumors, Chap. 6 on uveal tumors, Chap. 7 on retinal tumors, and Chap. 8 on systemic cancers are evident.

Dr. Hatem Krema is to be congratulated on organizing an excellent textbook on the topic of Ocular Oncology for residents, fellows, general ophthalmologists, and for all of us to read and digest. This all-encompassing book from the single-cell mutation that leads to an eye cancer to the clinical features and management of the cancer is exceptional. This book should be read and easily accessible on the bookshelf, an arm-length away, for every ophthalmologist for years to come.

Ocular Oncology Service
Wills Eye Hospital, Thomas Jefferson University
Philadelphia, PA, USA

Carol L. Shields
Jerry A. Shields

Preface

Ocular oncology is a disease-centered ophthalmic subspecialty that focuses on the diagnosis and management of tumors of the eye and related structures. This subspecialty has emerged because of the common bases underlying the pathogenesis and treatment approaches of various ophthalmic tumors, in addition to the rapid advances in the oncology sciences over recent decades. The primary objective in ocular oncology is to achieve tumor control while preserving as much of the ophthalmic structure and function as possible.

The practice of ocular oncology requires understanding and collaboration between the ocular oncologist and several other tumor-managing specialists, including radiation oncologists, radiation physicists, medical and pediatric oncologists, histopathologists, cytopathologists, and geneticists. The ocular oncologist's role is central in formulating the multidisciplinary treatment plan, implementing the ophthalmic treatment, coordinating the comprehensive care required for effective treatment, and managing any treatment-related ocular complications.

Recent decades have witnessed significant advancements in oncology, which have favorably impacted the diagnosis and management of several ophthalmic tumors.

Innovations in multimodal imaging of ocular tumors and fine biopsy techniques of extraocular and intraocular tumors, along with advances in cytopathology and immunohistochemistry, have greatly enhanced our diagnostic capabilities. A profound understanding of tumor biology, including the roles of genetics and epigenetics in tumor development and prognostication, coupled with new molecular diagnostic technologies, have contributed to more precise and personalized care for ophthalmic tumor patients.

Furthermore, standardized radiotherapy protocols for various tumors of the eye, adnexa, and orbit, together with the use of systemic and regional chemotherapy drugs and novel targeted therapy and immunotherapy medications, have revolutionized the treatment of ophthalmic tumors. Such new treatments provide higher tumor control rates and, in most cases, obviate the need for extensive or disfiguring surgeries.

This book is an updated, inclusive, and concise reference intended primarily for ocular oncology clinicians and trainees, general ophthalmologists, and allied cancer care specialists who manage ophthalmic tumors. I hope the reader will find it a comprehensive, resourceful guide in the field of ocular oncology.

Ocular Oncology Service
Princess Margaret Cancer Centre
University of Toronto
Toronto, ON, Canada

Hatem Krema

Acknowledgments

I am grateful to the late Dr. Danny Ghazarian, Dr. Zaid Saeed Kamil, and Dr. Bruno Fernandes for providing most of the pathology micrograph images in this book.

I am also thankful to Mr. Allan Connor, an ex-ophthalmic imaging specialist in my department, for some of the high-quality funduscopy, ultrasonography, and angiography images of our patients presented in this book.

About This Book

This book is an updated, single-volume, all-inclusive, concise reference in ocular oncology. It is addressed to ocular oncology specialists and trainees, general ophthalmologists, and allied cancer care specialists who manage ophthalmic tumors.

The book is divided into eight chapters. The first chapter is an introduction to oncology in general that covers basic concepts in cell biology, tumorigenesis, the hallmarks of cancer, and tumor pathology. The second chapter discusses the standard treatment methods employed in ocular oncology, including surgical approaches and techniques; treatment with physical energy such as radiotherapy, lasers, and cryotherapy; and the indications and toxicities of systemic and regional drug therapy. The following five chapters demonstrate the examination, classifications, clinical and imaging presentation, and current specific management options of tumors and relevant lesions that involve the eyelid, ocular surface, orbit, uveal tract, and retina. The final chapter highlights the direct and indirect impact of systemic cancers on the ophthalmic tissues and their management.

The book has been richly illustrated with over 350 original figures, schematic representations, and comparison tables.

Contents

1	Basics of Oncology	1
1	Fundamentals of Cell Biology and Cell Division	1
1.1	Regulation of the Cell Cycle	1
1.2	Cell Signaling (Cell-to-Cell Communication).....	3
2	Tumorigenesis and the Hallmarks of Cancer.....	6
2.1	Tumorigenesis (Oncogenesis)	6
2.2	Genetic Control of Tumorigenesis	6
2.3	Incomplete Penetrance and Variable Expressivity	7
2.4	Hereditary Cancer Predisposition	8
2.5	Role of Carcinogens.....	8
2.6	Tumour Epigenetics	9
2.7	Benign Versus Malignant Tumors	9
2.8	The Hallmarks of Cancer.....	9
3	Tumor Pathology	13
3.1	Taxonomy of Neoplasia.....	13
3.2	Tumor Histopathology.....	14
3.3	Tumor Cytopathology	17
3.4	Tumor Cytogenetics.....	18
3.5	Molecular Genomics	18
4	Tumor Grading and Staging.....	22
4.1	Tumor Grading.....	22
4.2	Tumor Staging	22
	References.....	23
2	Treatment Methods in Ocular Oncology	27
1	Principles of Surgical Treatment	27
1.1	Tumor Biopsy	27
1.2	Enucleation	38
1.3	Exenteration	43
2	Radiotherapy	46
2.1	Principles of Radiotherapy.....	46
2.2	Radiotherapy Methods.....	47
2.3	Ophthalmic Radiation Toxicity	57
3	Laser Treatment	61
3.1	The Principle of Laser Generation.....	61
3.2	Laser Effects on Tissues.....	61
3.3	The Variables That Influence Laser Impact	62
3.4	Laser Delivery Systems	62
3.5	Applications of Lasers in Ocular Oncology.....	63
4	Cryotherapy	64

5	Chemotherapy	65
5.1	Routes of Administration	66
5.2	Effectiveness of Systemic Chemotherapy	66
5.3	Applications of Chemotherapy Drugs in Ophthalmic Tumors	66
6	Targeted Therapy	68
6.1	The Hedgehog Pathway Inhibitors (HHI)	68
6.2	mTOR Pathway Inhibitors	68
6.3	BRAF Inhibitors	68
6.4	MEK Inhibitors	69
6.5	HIF- 2 α Inhibitor	69
6.6	Proteomase Inhibitors	69
6.7	Protein Kinase C Inhibitors	69
7	Immunotherapy	70
7.1	Monoclonal Antibodies (mAbs).	70
7.2	Immune Checkpoint Inhibitors (ICIs)	70
7.3	Immune-Modulating Drugs	71
7.4	Oncolytic Virus Therapy	71
7.5	Oncolytic Virus Therapy	72
7.6	Cancer Vaccines	72
	References.	72
3	Eyelid Tumors	77
1	Clinical Examination of the Eyelid Tumors.	77
1.1	History	77
1.2	Lesion Level.	78
1.3	Surface Features.	78
1.4	Palpation	78
1.5	Transillumination.	78
1.6	Regional Lymph Node.	78
1.7	Associated Findings.	78
2	Epidermal Tumors	78
2.1	Benign Lesions.	78
2.2	Premalignant Lesions.	81
2.3	Malignant Tumors	82
3	Sebaceous Gland Tumors.	89
3.1	Non-neoplastic Sebaceous Gland Lesions	89
3.2	Neoplastic Sebaceous Gland Tumors.	89
4	Melanocytic Tumors	92
4.1	Eyelid Melanocytic Nevus.	93
4.2	Eyelid Melanoma.	95
5	Neural Tumors	99
5.1	Solitary Neurofibroma	99
5.2	Plexiform Neurofibroma	99
5.3	Schwannoma (Neurilemmoma).	99
5.4	Merkel Cell Carcinoma	101
6	Vascular Tumors.	102
6.1	Congenital Capillary Hemangioma	102
6.2	Acquired Capillary Hemangioma	103
6.3	Cherry Angioma.	104
6.4	Cavernous Hemangioma	104
6.5	Nevus Flammeus (Port Wine Stain).	104

6.6	Eyelid Lymphangioma (Lymphaticovenous Malformation)	105
6.7	Hemangioendothelioma	105
6.8	Kaposi Sarcoma	105
7	Sweat Gland Tumors	106
7.1	Non-neoplastic Sweat Gland Lesions	106
7.2	Neoplastic Sweat Gland Tumors	106
8	Hair Follicle Tumors	107
8.1	Trichoadenoma of Nikolowski	108
8.2	Pilar Cyst	109
8.3	Trichofolliculoma	109
9	Lesions and Tumors of the Eyelid Stroma	109
9.1	Non-neoplastic Eyelid Stromal Lesions	109
9.2	Neoplastic Eyelid Stromal Tumors	110
10	Infiltrative and Metastatic Eyelid Tumors	111
10.1	Eyelid Lymphoma	111
10.2	Eyelid B-Cell Lymphoma	111
11	Management of Eyelid Tumors	112
11.1	Surgical Treatment	113
11.2	Radiotherapy	123
11.3	Fractionated Photon EBRT	124
11.4	Medical Therapy	126
11.5	Cryosurgery	126
	References	128
4	Ocular Surface Tumors	133
1	Evaluation of Conjunctival Tumors	133
2	Tumors of the Ocular Surface Epithelium	135
2.1	Benign Surface Epithelium Lesions	135
2.2	Malignant Surface Epithelium Tumors	137
3	Melanocytic Tumors	142
3.1	Conjunctival Nevus	142
3.2	Racial (Complexion-Associated) Melanosis	143
3.3	Ocular Melanocytosis	143
3.4	Primary Acquired Melanosis	144
3.5	Conjunctival Melanoma	145
4	Lymphoproliferative Tumors	149
5	Vascular Tumors	151
5.1	Lymphangioma	151
5.2	Pyogenic Granuloma	153
5.3	Capillary Hemangioma	153
5.4	Cavernous Hemangioma	153
5.5	Acquired Sessile Hemangioma	153
5.6	Racemose Hemangioma	153
5.7	Kaposi Sarcoma	154
6	Myogenic Tumors	154
6.1	Conjunctival Rhabdomyosarcoma	154
6.2	Conjunctival Leiomyosarcoma	155
7	Neural Tumors	155
7.1	Conjunctival Schwannoma	155
7.2	Conjunctival Neurofibroma	155
8	Ocular Surface Choristomas	156
8.1	Dermolipoma	156
8.2	Epibulbar Dermoid	156

8.3	Epibulbar Osseous Choristoma	157
8.4	Lacrimal Gland Choristoma.	157
8.5	Complex Choristoma	157
9	Conjunctival Cystic Lesions	159
9.1	Inclusion (Implantation) Cysts.	159
9.2	Other Conjunctival Cystic Lesions	159
10	Conjunctival Stromal Tumors	160
10.1	Conjunctival Myxoma	160
10.2	Histiocytic Tumors.	160
10.3	Fibrous Tumors	161
10.4	Lipomatous Tumors	161
11	Tumors of the Caruncle	161
12	Treatment of Ocular Surface Tumors.	162
12.1	Surgical Treatment.	163
12.2	Cryotherapy	165
12.3	Radiotherapy	166
12.4	Drug Therapy.	169
	References.	170
5	Orbital Tumors	175
1	Evaluation of Orbital Tumors	175
1.1	Clinical Examination of the Orbit (7 Ps).	175
1.2	Imaging of the Orbital Tumors	176
1.3	Classification of the Orbital Tumors	177
2	Lacrimal Gland Lesions.	178
2.1	Pleomorphic Adenoma (Benign Mixed Tumor)	178
2.2	Acute Dacryoadenitis.	184
3	Circumscribed Orbital Lesions	186
3.1	Cavernous Haemangioma (Cavernous Venous Malformation)	186
3.2	Neurofibroma.	186
3.3	Schwannoma (Neurilemmoma).	187
3.4	Solitary Fibrous Tumor	188
4	Diffuse Orbital Lesions	191
4.1	Sarcoidosis	195
4.2	Orbital Tuberculosis.	195
4.3	ANCA-Associated Vasculitis.	196
4.4	IgG4-Related Diseases.	197
4.5	Angiolymphoid Hyperplasia with Eosinophilia (AHLE) and Kimura's Disease	198
4.6	Histiocytosis.	198
5	Orbital Cysts	204
5.1	Dermoid/ Epidermoid Cyst	204
5.2	Conjunctival Implantation Cyst.	205
5.3	Hematic Cyst	205
5.4	Parasitic Cysts	205
5.5	Paranasal Sinus Mucocele	206
5.6	Meningocele/Encephalocele	206
5.7	Congenital Cystic Eye/Microphthalmia with Cyst	207
6	Optic Nerve Tumors.	207
6.1	Optic Nerve Glioma.	207
6.2	Optic Nerve Sheath Meningioma.	209
6.3	Rare Optic Nerve Tumors	210

7	Pediatric Orbital Lesions	213
7.1	Infantile Dermoid Cyst	213
7.2	Orbital Teratoma	213
8	Orbital Bone Tumors	216
8.1	Fibrous Dysplasia	216
8.2	Osteoma	217
8.3	Brown Tumor	217
8.4	Aneurysmal Bone Cyst	217
8.5	Cholesterol Granuloma	217
9	Treatment of Orbital Tumors	218
9.1	Surgical Treatment	218
9.2	Radiotherapy	223
9.3	Medical Therapy	224
9.4	Sclerotherapy of Vascular Lesions	224
	References	225
6	Uveal Tumors	231
1	Imaging of Intraocular Tumors	231
1.1	Fundus Photography	231
1.2	Ultrasonography	231
1.3	Optical Coherence Tomography (OCT)	234
1.4	Fundus Fluorescein Angiography (FFA)	234
1.5	Indocyanine Green Angiography (ICGA)	235
1.6	Fundus Autofluorescence (FAF)	235
2	Iris Tumors	237
2.1	Melanocytic Iris Lesions	237
2.2	Non-melanocytic Iris Lesions	240
2.3	Iris Cysts	243
3	Ciliary Body Tumors	244
3.1	Ciliary Body Melanoma	244
3.2	Ciliary Body Melanocytoma	247
3.3	Ciliary Body Leiomyoma	247
3.4	Ciliary Body Schwannoma	247
3.5	Ciliary Body Adenomas	249
4	Choroidal Melanotic Tumors	249
4.1	Choroidal Nevus	249
4.2	Choroidal Melanocytoma	252
4.3	Choroidal Indeterminate Melanocytic Lesion (IML)	253
4.4	Choroidal Melanoma	254
5	Choroidal Amelanotic Tumors	271
5.1	Choroidal Metastasis	271
5.2	Choroidal Granuloma	271
5.3	Choroidal Lymphoma	273
6	Choroidal Vascular Tumors	274
6.1	Circumscribed Choroidal Hemangioma	274
6.2	Diffuse Choroidal Hemangioma	277
6.3	Choroidal Macrovascular	279
7	Calcified Choroidal Tumors	280
7.1	Choroidal Osteoma	280
7.2	Sclerochoroidal Calcification	282
	References	283

7	Retinal Tumors	291
1	Retinal Melanotic Tumors	291
1.1	Primary Tumors and Congenital Lesions of the RPE	291
1.2	Optic Disc Melanocytoma	296
1.3	Metastatic Cutaneous Melanoma to the Retina and Vitreous	298
2	Retinal Vascular Tumors	300
2.1	Retinal Capillary Hemangioblastoma (RCH)	300
2.2	Retinal Vasoproliferative Tumor (Focal Nodular Reactive Gliosis)	302
2.3	Retinal Racemose Hemangioma	303
3	Retinal Amelanotic Tumors	305
3.1	Vitreoretinal Lymphoma	305
3.2	Retinal Gliotic Lesions	307
3.3	Amelanotic Retinal Metastasis	309
4	Retinal Calcified Tumors	310
4.1	Retinal Gliotic Lesions	310
4.2	Retinoblastoma	314
5	Optic Disc Tumors	342
	References	344
8	The Eye in Systemic Cancers	351
1	Metastasis to the Ophthalmic Tissues	351
1.1	Intraocular Metastasis	351
1.2	Metastasis to the Orbit and Ocular Adnexa	354
2	The Eye in the Hematopoietic Cancers	357
2.1	Leukemia	357
2.2	Lymphoproliferative Disorders	359
2.3	Plasma Cell Neoplasia	361
2.4	Histiocytosis	363
3	The Effect of the Immunocompromised State on the Eye	366
3.1	Activation of Opportunistic Infections	366
3.2	Eye Tumors in the Immunocompromised Patients	371
4	Autoimmune Reaction in Systemic Cancers	372
4.1	Graft Versus Host Disease	372
4.2	Paraneoplastic Ophthalmic Syndromes	374
4.3	Paraneoplastic Optic Neuropathy (PON)	377
5	The Ocular Side Effects of the Head and Neck Radiotherapy	379
6	Ocular Side Effects of Systemic Cancer Drug Therapy	381
6.1	The Ocular Side Effects of Systemic Chemotherapy (the Cytotoxic Agents)	381
6.2	The Ocular Side Effects of Systemic Targeted Therapy	381
6.3	The Ocular Side Effects of Systemic Immunotherapy	382
	References	385
	Index	389

About the Author

Hatem Krema, MD, MSc, FRCS, FICO (Hon.) Professor Dr. Hatem Krema is the director of the ocular oncology program at the hospitals of the University of Toronto, Canada.

He has over 25 years of profound experience in ocular oncology practice. He was trained in ocular oncology at the Royal Liverpool University Hospital, England, United Kingdom; Wills Eye Institute of Thomas Jefferson University, Philadelphia, Pennsylvania, USA; and Princess Margaret Cancer Centre of the University of Toronto.

Dr. Krema is interested in translational clinical research in ophthalmic oncology. He focuses on developing combined multimodal treatment protocols for ocular, adnexal, and orbital cancers, introducing innovative surgical techniques, establishing management algorithms for treatment complications, and applying molecular genomics to the personalized care of ophthalmic tumor patients.

Dr. Krema is frequently invited as a guest speaker and moderator at several national and international conferences. He is an ad hoc peer reviewer for several high-ranked ophthalmology journals and has served as the ocular oncology section editor for the *Canadian Journal of Ophthalmology* for 15 years.

He has mentored several international ocular oncology fellows, has been invited to provide courses and teaching sessions in ocular oncology to residents and fellows in several countries, and was granted several national and international teaching awards.